TrialBreast cancer research : BCR2017
Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer.
Giampaolo Bianchini et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
76 papers cite itlatest 60 shown
this paperpooled ittrialcites it